AstraZeneca PLC

64.49+1.35+2.14%Vol 5.58M1Y Perf 14.36%
May 16th, 2022 16:00 DELAYED
BID63.80 ASK64.51
Open63.35 Previous Close64.49
Pre-Market- After-Market64.31
 - -  -0.19 -0.29%
Target Price
74.25 
Analyst Rating
Strong Buy 1.40
Potential %
15.13 
Finscreener Ranking
★★     46.46
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     41.40
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     40.15
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★+     48.38
Price Range Ratio 52W %
60.10 
Earnings Rating
Strong Buy
Market Cap199.85B 
Earnings Date
29th Apr 2022
Alpha0.01 Standard Deviation0.06
Beta0.45 

Today's Price Range

63.3564.80

52W Range

53.6371.70

5 Year PE Ratio Range

19.20126.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
1.34%
1 Month
-6.60%
3 Months
5.74%
6 Months
11.71%
1 Year
14.36%
3 Years
70.70%
5 Years
88.73%
10 Years
263.11%

TickerPriceChg.Chg.%
AZN64.491.35002.14
AAPL145.54-1.5700-1.07
GOOG2 295.85-34.4600-1.48
MSFT261.500.38000.15
XOM90.952.09002.35
WFC42.21-0.4300-1.01
JNJ178.081.23000.70
FB200.041.42000.71
GE74.63-0.4200-0.56
JPM118.26-0.8300-0.70
ValuationValueIndustryS&P 500US Markets
-185.70
5.38
5.28
25.90
-20.80
2.44
-7.86
11.73
219.79B
Forward PE17.10
PEG-11.46
Financial StrengthValueIndustryS&P 500US Markets
0.30
1.00
0.44
0.86
0.00
Leverage Ratio 2.90
ProfitabilityValueIndustryS&P 500US Markets
66.10
0.00
16.90
6.90
-2.48
RevenueValueIndustryS&P 500US Markets
37.87B
12.22
16.49
9.31
DividendsValueIndustryS&P 500US Markets
2.99
1.93
0.24
0.11
Payout ratio93.00
Earnings HistoryEstimateReportedSurprise %
Q01 20220.860.9510.47
Q04 20210.770.849.09
Q03 20210.630.54-14.29
Q02 20210.450.450.00
Q01 20210.710.8114.08
Q04 20200.530.541.89
Q03 20200.490.47-4.08
Q02 20200.440.489.09
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.7813.04Positive
9/2022 QR0.8112.50Positive
12/2022 FY3.342.77Positive
12/2023 FY3.77-1.31Negative
Next Report Date-
Estimated EPS Next Report0.84
Estimates Count4
EPS Growth Next 5 Years %16.20
Volume Overview
Volume5.58M
Shares Outstanding3.10M
Shares Float3.10B
Trades Count51.72K
Dollar Volume359.03M
Avg. Volume7.63M
Avg. Weekly Volume7.73M
Avg. Monthly Volume7.31M
Avg. Quarterly Volume7.83M

AstraZeneca PLC (NYSE: AZN) stock closed at 64.49 per share at the end of the most recent trading day (a 2.14% change compared to the prior day closing price) with a volume of 5.58M shares and market capitalization of 199.85B. Is a component of NASDAQ 100 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 76100 people. AstraZeneca PLC CEO is Pascal Soriot.

The one-year performance of AstraZeneca PLC stock is 14.36%, while year-to-date (YTD) performance is 10.71%. AZN stock has a five-year performance of 88.73%. Its 52-week range is between 53.63 and 71.7, which gives AZN stock a 52-week price range ratio of 60.10%

AstraZeneca PLC currently has a PE ratio of -185.70, a price-to-book (PB) ratio of 5.38, a price-to-sale (PS) ratio of 5.28, a price to cashflow ratio of 25.90, a PEG ratio of 2.32, a ROA of -1.32%, a ROC of -0.09% and a ROE of -4.25%. The company’s profit margin is -2.48%, its EBITDA margin is 16.90%, and its revenue ttm is $37.87 Billion , which makes it $12.22 revenue per share.

Of the last four earnings reports from AstraZeneca PLC, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.84 for the next earnings report. AstraZeneca PLC’s next earnings report date is -.

The consensus rating of Wall Street analysts for AstraZeneca PLC is Strong Buy (1.4), with a target price of $74.25, which is +15.13% compared to the current price. The earnings rating for AstraZeneca PLC stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AstraZeneca PLC has a dividend yield of 2.99% with a dividend per share of $1.93 and a payout ratio of 93.00%.

AstraZeneca PLC has a Neutral technical analysis rating based on Technical Indicators (ADX : 8.92, ATR14 : 1.57, CCI20 : -44.54, Chaikin Money Flow : 0.03, MACD : -0.88, Money Flow Index : 48.96, ROC : -4.06, RSI : 47.96, STOCH (14,3) : 55.63, STOCH RSI : 1.00, UO : 54.61, Williams %R : -44.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AstraZeneca PLC in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (66.67 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
2 (33.33 %)
2 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Moderate Buy
1.67
Strong Buy
1.57

AstraZeneca PLC

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

CEO: Pascal Soriot

Telephone: +44 2037495000

Address: 1 Francis Crick Avenue, Cambridge CB2 0AA, , GB

Number of employees: 76 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

TipRanks News for AZN

Wed, 04 May 2022 12:41 GMT AstraZeneca (AZN) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Sat, 30 Apr 2022 03:49 GMT AstraZeneca (AZN) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Mon, 14 Mar 2022 12:40 GMT FDA Approves AstraZeneca and Mercks LYNPARZA

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 07:56 GMT AstraZeneca Acquires Neurimmunes Heart Failure Drug Candidate

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 14:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: AstraZeneca (AZN), Bruker (BRKR) and Neurocrine (NBIX)

- TipRanks. All rights reserved.

Sun, 13 Feb 2022 14:46 GMT Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AstraZeneca (AZN) and Dexcom (DXCM)

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 12:45 GMT AstraZenecas Q4 Results Outperform Shares Rise Pre-Market

- TipRanks. All rights reserved.

Tue, 25 Jan 2022 10:27 GMT AstraZeneca Announces Orphan Drug Designation for Eplontersen in the U.S.

- TipRanks. All rights reserved.

Mon, 03 Jan 2022 17:15 GMT AstraZeneca: Strong Growth, Balanced Pipeline, Rich Valuation

- TipRanks. All rights reserved.

News

Stocktwits